TVGN

Tevogen Bio Holdings Inc. (TVGN) - Q1 2025 10-Q Summary

Business Context and Reporting Period

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies (ExacTcell technology) for infectious diseases and cancers. The primary product candidate, TVGN 489, targets high-risk COVID-19 patients. This report covers the quarterly period ended March 31, 2025. The Company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Shift: The Company reported a net loss of $10.4 million in Q1 2025, compared to a net income of $11.3 million in Q1 2024. The prior year income was driven by a non-cash gain of $48.5 million from the change in fair value of convertible promissory notes and $7.5 million in merger transaction costs, neither of which occurred in Q1 2025.
• Expense Reduction: Total operating expenses decreased significantly to $10.4 million from $29.5 million. This reduction is primarily due to a decrease in stock-based compensation (from $26.3 million to $7.3 million) and the absence of merger transaction costs.
• Liquidity Improvement: Cash balances increased by approximately $692,000 during the quarter, supported by $2.0 million in proceeds from a Loan Agreement and a $2.0 million capital contribution (grant) from KRHP LLC.
• Debt Position: The Company drew an additional $2.0 million under its Loan Agreement in Q1 2025, increasing the total loan agreement liability to $3.0 million. Notes payable of $1.65 million remain outstanding and are in default, though no immediate transfer of shares or payment is required per default provisions.

Outlook, Risks, and Management Commentary

• Liquidity and Funding: Management believes current cash ($2.0 million), the remaining $27.0 million available under the Loan Agreement (with $1.0 million monthly draw capacity), and a committed $8.0 million grant from KRHP LLC are sufficient to fund operations for at least the next 12 months. The Company does not plan to initiate new clinical trials until additional funding is secured.
• Operational Status: The Company has completed a Phase 1 proof-of-concept trial for TVGN 489. No revenue is expected until marketing approval is obtained.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses in internal control over financial reporting.
• Risks: Key risks include the inability to raise additional capital on acceptable terms, the uncertainty of clinical trial outcomes, and the potential need to delay or reduce R&D programs if funding is insufficient.
• Subsequent Events: In April 2025, the Company entered into a Master Services and Facilities Agreement with CD 8 Technology Services LLC (related party) for manufacturing access and drew an additional $0.5 million on the Loan Agreement.

Investor Verification Checklist

• Capital Adequacy: Verify the timing and certainty of the remaining $8.0 million grant commitment from KRHP LLC and the ability to draw the full $27.0 million under the Loan Agreement.
• Default Status: Confirm the status of the $1.65 million notes payable to Polar Multi-Strategy Master Fund, which are in default, and assess any potential legal or financial repercussions.
• Internal Controls: Review the specific material weaknesses in internal controls disclosed in Item 4 and the remediation plan.
• Related Party Transactions: Scrutinize the terms of the Loan Agreement and preferred stock issuances to The Patel Family, including the purchase options and interest settlement in stock.
• Stock-Based Compensation: Monitor the impact of the $79.9 million in unrecognized stock-based compensation costs, which will be expensed over a weighted average of 8.2 years.